“…Luciani et al [18] presented a study of 2.5 mg of naratriptan given during the prodromal phase of migraine in an open-label study of 20 patients. Use of naratriptan at that stage produced a 60% reduction in the occurrence of the subsequent migraine attack.…”
Section: Treatment Of the Migraine Prodromementioning
The use of triptans has improved the ability to treat migraine successfully compared with older treatments. Speed of relief, consistency of effect, and good tolerability have been the hallmarks of these agents. All of the currently available triptans have comparable efficacy and tolerability. Variables between the agents may lead to one agent or dose form being preferred over another in various clinical scenarios. The triptans that are forthcoming may improve on these options through enhanced efficacy rates, tolerability, and headache recurrence rates. There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack. Additionally, recent work suggests that mini-prophylaxis of migraine at the menses is a highly successful treatment option with the triptans. In this age of managed care, providing cost-effective treatment of headache will take on increasing importance. Techniques such as stratification of acute treatments may enhance cost-effective care, whereas ready availability of the triptans may lead to significant improvements in utilization of parameters such as office visits, emergency room treatment, and even hospitalization.
“…Luciani et al [18] presented a study of 2.5 mg of naratriptan given during the prodromal phase of migraine in an open-label study of 20 patients. Use of naratriptan at that stage produced a 60% reduction in the occurrence of the subsequent migraine attack.…”
Section: Treatment Of the Migraine Prodromementioning
The use of triptans has improved the ability to treat migraine successfully compared with older treatments. Speed of relief, consistency of effect, and good tolerability have been the hallmarks of these agents. All of the currently available triptans have comparable efficacy and tolerability. Variables between the agents may lead to one agent or dose form being preferred over another in various clinical scenarios. The triptans that are forthcoming may improve on these options through enhanced efficacy rates, tolerability, and headache recurrence rates. There exist increasing options for migraine treatment that may further improve the clinical effects of the older and newer triptans through early treatment of migraine at the stages of mild migraine pain, or even during the prodromal phase of the attack. Additionally, recent work suggests that mini-prophylaxis of migraine at the menses is a highly successful treatment option with the triptans. In this age of managed care, providing cost-effective treatment of headache will take on increasing importance. Techniques such as stratification of acute treatments may enhance cost-effective care, whereas ready availability of the triptans may lead to significant improvements in utilization of parameters such as office visits, emergency room treatment, and even hospitalization.
“…[11][12][13][14] Identifying the prodrome can be particularly helpful because acute treatment during the prodrome or prior to the painful stage of migraine can reduce the severity of the headache phase or prevent the development of a full migraine attack. [15][16][17][18][19] A previous small cases series (N = 8) catalogued behaviors in companion pet dogs that their owners with migraine identified as being linked with migraine episodes. 20 Unique alerting behaviors were consistently identified within minutes to 24 hours before the onset of migraine symptoms.…”
Objectives: Anecdotal reports suggest that changes in dog behavior might be used to predict impending migraine episodes. This survey was designed to investigate how companion dogs react to migraines that occur in their owners. Design: Online survey was available from January 4-31, 2012. Settings/location: Survey was conducted through SurveyMonkey, with links to the survey posted at Migraine.com and promoted through social media. Subjects: Adults ‡ 18 years old who experience migraine episodes and live with a dog were eligible to participate. Interventions and outcome measures: Participants completed an 18-question online survey that asked about participant demographics, migraines, and their dog's behavior before or during migraine episodes. Results: The survey was completed by 1029 adult migraineurs (94.9% women), with migraines typically occurring £ 8 days per month in 63.4% of participants. A recognized change in the dog's behavior prior to or during the initial phase of migraine was endorsed by 552 participants (53.7%), most commonly unusual attentiveness to the owner (39.9%). Among the 466 participants providing details about their dog's behavior with their migraines, 57.3% were able to identify dog alerting behavior before symptoms of a migraine attack would typically begin, with changes usually noticed within 2 hours before the onset of initial migraine symptoms. The dog's behavior was considered to be often or usually linked with the development of a migraine for 59.2% of migraineurs, and 35.8% of migraineurs endorsed beginning migraine treatments after the dog's behavior was recognized and before migraine symptoms had started. Participant demographics, migraine frequency, and breed of dog in the home were similar between the 470 participants with no alerting behavior endorsed and the 466 participants providing detailed alerting information. Conclusions: About one in four migraineurs living with a companion dog endorsed recognizing a change in their dog's behavior before recognizing initial symptoms of a migraine attack.
“…Only one study exists in individuals with inevitable headache following prodrome. Preheadache treatment with naratriptan eliminated 60% of all headaches and reduced moderate-severe occurrence from 95% to 23% [45]. Clinical experience, but not scientific study, suggests that modest doses of anti-inflammatory drugs seem to be successful in prodrome as well.…”
The optimal acute treatment of migraine requires recognition of the multitude of migraine presentations, the frequency of total attacks, and number of days of headache disability. These initial diagnostic steps are initiated in the waiting room, but phase-specific and stratified treatment selection requires having mutual understanding, trust, and belief through extensive discussion. The imperative acute treatment goal must be to treat early, but not too often, a fact represented by a 75% or better occurrence of pain freedom at 2 hours with two or fewer drug doses averaging 2 or fewer days a week. Migraine-specific therapy best wins the race against time and allodynia. Employing this formulary, multiple triptan formulations and phase and stratified patient-centered therapy creates success.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.